Common Brand Name
Isentress, known generically as raltegravir, stands as a cornerstone in the therapeutic arsenal against HIV. Available in various dosages, such as Isentress 400 mg, it was the first integrase inhibitor approved by the FDA. This groundbreaking drug effectively inhibits the integration of viral DNA into the host genome, a crucial step in viral replication. Isentress is manufactured by Merck & Co., a company with a longstanding commitment to advancing antiretroviral therapy. The brand has become synonymous with innovative HIV treatment options.
Correct Use
Isentress 400 mg is administered orally, typically in combination with other antiretroviral agents. The standard adult dosage involves taking the tablet twice daily, with or without food. Consistent adherence to the prescribed regimen maximizes therapeutic efficacy and minimizes the risk of developing resistance. It’s imperative to swallow the tablet whole, without crushing or chewing. Monitoring the patient’s viral load and CD4 count is crucial to evaluate the response to treatment. Detailed dosage instructions can be found on the Drugs.com website.
Who Can and Cannot Take Isentress
Isentress is primarily indicated for individuals diagnosed with HIV-1 infection, both in treatment-naïve and treatment-experienced patients. Pediatric patients aged four weeks and older may also receive the drug, provided they weigh at least 3 kg. Contraindications include known hypersensitivity to raltegravir or any component of the formulation. Pregnant individuals should consult healthcare providers to weigh potential risks and benefits. Isentress is generally not recommended for patients with severe hepatic impairment due to limited data on safety in this population.
Cautions with Other Medicines
Co-administration of Isentress with certain drugs necessitates caution. Enzyme inducers such as rifampin can reduce raltegravir levels, potentially compromising its efficacy. Concurrent use with divalent cation-containing antacids may also decrease absorption. Healthcare providers should be informed of all concurrent medications to preclude adverse interactions. Close monitoring and dose adjustments might be necessary when combining Isentress with other antiretrovirals.
Toxicity
Isentress 400 mg exhibits a favorable safety profile, but like any medication, it can lead to adverse effects. The most common include insomnia, headache, and nausea. Rarely, severe allergic reactions or liver enzyme elevations may occur. Prompt medical attention is essential if serious side effects manifest. Regular liver function tests are advisable during treatment. Adhering to prescribed dosages mitigates toxicity risks.
Purchasing Isentress Without a Prescription
Acquiring Isentress 400 mg without a prescription poses significant risks. Legally, it should be dispensed only upon a valid prescription due to its status as a controlled medication. Buying from unverified sources can lead to counterfeit drugs, posing severe health hazards. Patients should always consult healthcare professionals to obtain Isentress through legitimate channels. Ensuring authenticity and proper guidance is crucial for effective and safe HIV management.
| Dosage | Indication | Administration |
|---|---|---|
| Isentress 400 mg | HIV-1 infection | Twice daily, oral |
Important Considerations
When taking Isentress, keep these points in mind:
- Ensure regular follow-ups with healthcare providers.
- Report any unusual symptoms immediately.
- Avoid self-medication and unauthorized sources.